Estudio comparativo de la produccion de vacunas idiotipicas para linfoma folicular obtenidas mediante fusion celular y por tecnicas recombinantes

Resumen

Follicular lymphoma (FL) is a haematologic neoplàsia of B cells which usually presents a good response to conventional chemotherapy and/or radiation treatment. Unfortunately, it is also characterized by subsequent relapses after treatment. Hence, is still considered incurable. The constant search for new therapeutic strategies for human malignancies, together with a better knowledge of the immune system, has lead to the emergence or a new discipline: immunotherapy. In the case of FL, the malignant celi is a B, that is a cell belonging to the same immune system. The antigenic determinants generated as a consequence of v(d)j recombination make each immunoglobulin specific for each B-cell clone. Therefore, the id may be considered an ideal tumor-specific antigen to develop immunotherapy against. The main problem is that its conventional production does not guarantee that we shall be able to produce it for all FL patients; so, in this study, a method of generation of idiotype recombinant vaccines was developed. This new type of production could also considerably reduce the time patients have to wait before they can start immunotherapy, and allow the vaccination protocol to be extended for patients who need it. Before applying idiotype recombinant vaccines in humans, a comparative study of structure/antigenecity of the proteins produced by traditional and recombinant method was carried out. The protection against a preclinical model of B-cell lymphoma with a protocol of recombinant idiotypic vaccination was also performed.